Eloxx Pharmaceuticals, Inc.(ELOX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $6.4M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ELOX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Eloxx Pharmaceuticals, Inc. (ELOX), a Healthcare sector company. ELOX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $6.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), Eloxx Pharmaceuticals, Inc. reports net income of $-3.8M, free cash flow of $-5.5M. ELOX trades on the Nasdaq exchange and files with the SEC under CIK 1035354. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELOX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eloxx Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-3.8M
Free Cash Flow
Q1 2026
$-5.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+91.0% YoYOperating Income
+90.2% YoYEPS (Diluted)
+86.0% YoYTotal Assets
-88.3% YoYTotal Debt
-83.3% YoYOp. Cash Flow
+81.9% YoY| Metric | FY 2025 | FY 2021 | FY 2020 | FY 2018 | FY 2016 |
|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — |
| Net Income | $-6.0M +91.0% | $-66.7M -93.0% | $-34.6M +26.7% | $-47.2M -379.2% | $-9.8M |
| Operating Income | $-6.4M +90.2% | $-66.0M -97.3% | $-33.5M +29.7% | $-47.6M -383.4% | $-9.8M |
| EPS (Diluted) | $-5.34 +86.0% | $-38.15 | — | — | — |
| Total Assets | $5.3M -88.3% | $45.1M +70.5% | $26.5M -47.8% | $50.7M +1521.4% | $3.1M |
| Total Debt | $2.0M -83.3% | $12.0M -24.8% | $16.0M | — | — |
| Operating Cash Flow | $-6.3M +81.9% | $-35.0M -24.3% | $-28.2M +10.2% | $-31.4M -254.7% | $-8.8M |
AI Insight: ELOX Financial Trends
Eloxx remains pre-revenue with persistent quarterly losses and negative equity, though debt has contracted sharply from $16M to $0M.
• Total debt fell from $16M (Q4 2022) to $0M (Q1 2026), eliminating leverage. Operating losses narrowed from $-10M to $-4M over same period.
• Operating cash burn stabilized at $-5M to $-7M quarterly (Q1 2023–Q1 2026), showing consistency but no improvement in cash generation.
• Negative equity worsened from $-11M (Q4 2022) to $-12M (Q4 2025), then improved to $-8M (Q1 2026), indicating accumulated losses exceed assets.
⚠ No revenue generation across entire 2022–Q1 2026 period signals sustained clinical/commercial delays or lack of marketable products.
⚠ Equity remains deeply negative despite debt elimination; solvency depends entirely on future funding or asset sales.
AI Insight: ELOX Ratio Trends
Insufficient financial data to establish trend analysis — nearly all profitability and efficiency metrics missing across the period.
• D/E ratio of 6.93 recorded in Q2 2022; all other leverage and profitability metrics absent from available data.
⚠ Sparse financial disclosure prevents assessment of margin trajectory, cash generation, or return on capital trends.
Get alerted when ELOX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Eloxx Pharmaceuticals, Inc. including:
Top Institutional Holders of ELOX
Activest Wealth Management
$56.004 shSBI Securities Co., Ltd.
$28.002 sh
| Fund | Value | Shares |
|---|---|---|
| Activest Wealth Management | $56.00 | 4 |
| SBI Securities Co., Ltd. | $28.00 | 2 |
More Healthcare Companies
View all Healthcare →Put ELOX on your watchlist
Track score changes the day Eloxx Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ELOX a good stock to buy?
13F Pro's AI-powered analysis of Eloxx Pharmaceuticals, Inc. (ELOX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELOX are available on the ELOX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ELOX is classified as a small company.
Which hedge funds own ELOX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELOX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Eloxx Pharmaceuticals, Inc.'s investment landscape.